SCHEDULE 13G: BlackRock Discloses 5.7% Passive Stake in Inhibrx Biosciences
Beneficial Ownership Disclosure
BlackRock, Inc. has reported a passive beneficial ownership of 5.7% of Inhibrx Biosciences, Inc.'s common stock as of December 31, 2024.
Summary
- BlackRock, Inc. filed a Schedule 13G, indicating beneficial ownership of Inhibrx Biosciences, Inc. common stock.
- As of December 31, 2024, BlackRock beneficially owned an aggregate of 831,807 shares of Inhibrx Biosciences, Inc. common stock.
- This ownership represents 5.7% of the total outstanding common stock of Inhibrx Biosciences, Inc.
- BlackRock holds sole voting power over 822,613 shares and sole dispositive power over 831,807 shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.
- Several BlackRock subsidiaries, including BlackRock Advisors, LLC, Aperio Group, LLC, and BlackRock Institutional Trust Company, National Association, are identified as entities that acquired the security.
Sentiment
Score: 6
Explanation: The disclosure of a significant passive stake by a major institutional investor like BlackRock is generally viewed as a positive signal of confidence in the company, although it does not provide operational or financial performance details.
Positives
- BlackRock, a major institutional investor, holding a significant stake (5.7%) in Inhibrx Biosciences, Inc. may signal confidence in the company's long-term prospects.
- The filing indicates a passive investment, suggesting BlackRock is not seeking to influence control, which can be viewed as a stable, long-term holding by a prominent asset manager.
Future Outlook
This Schedule 13G filing does not contain forward-looking statements or guidance regarding Inhibrx Biosciences, Inc.'s future performance or outlook, as it is a disclosure of current beneficial ownership by an institutional investor.
Industry Context
The filing indicates a significant institutional investment in Inhibrx Biosciences, Inc., a company likely operating in the biotechnology or pharmaceutical sector given its name. Such investments by major asset managers like BlackRock are common across various industries and can reflect a belief in the long-term growth potential of the company within its specific market segment.
Stakeholder Impact
- Shareholders: May view BlackRock's significant stake as a vote of confidence, potentially leading to increased investor interest or stability in the stock.
- Company Management: Awareness of a major institutional holder like BlackRock, though passive, can influence strategic considerations and investor relations.
Key Dates
| Date | Description |
|---|---|
| 04/30/2023 | Date of previously revoked Power of Attorney for BlackRock, Inc. |
| 01/21/2025 | Date of execution of the new Power of Attorney by BlackRock, Inc. |
| 12/31/2024 | Date of event which requires filing of this statement (reporting period end date). |
| 02/04/2025 | Date of filing of this statement. |
Keywords
Inhibrx Biosciences, BlackRock, Schedule 13G, beneficial ownership, common stock, institutional investment, passive stake, SEC filing, biotechnology, pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.